ScripsAmerica, Inc. (OTCMKTS:SCRC) recently saw a nice run after the Company announced their managed specialty pharmacy reported $5,457,137 in approved orders during the month of September 2014. The pharmacy’s September revenue represented a 12% increase over the previous month and increased its annual run rate to over $65 million.
On March 5 SCRC said their Florida-based pharmaceutical distributor, PIMD International LLC, (“PIMD”), reported $554,411 in revenue during the month of February 2015.
PIMD’s February sales were 305% higher than January and represent the company’s second consecutive month of achieving record high revenues.
In December 2014, the Company acquired a 90% interest in PIMD, which serves as a pharmaceutical wholesaler distributor to pharmacies, hospitals, and physician’s offices in the U.S., providing ScripsAmerica’s customers and end users with access to specific medications.
ScripsAmerica, Inc. (OTCMKTS:SCRC) highly efficient marketing and distribution platform provides their clients with competitive pricing and seamless access to a broad customer base. SCRC has built strong relationships across the entire drug distribution chain, from the wholesalers and manufacturers to the end distribution outlets, allowing it to achieve minimum turn-around time and maximum shelf-life for its products.
SCRC has been putting out a number of significant press releases in recent weeks including the one on June 3 that started it all; they announced that the Company has begun discussions with Forbes Investment Ltd. to market, supply, distribute and adapt its RapiMed(R) products throughout China. According to Kline and Company, the Chinese OTC market is valued at over $32 Billion Dollars.
To Find out the inside Scoop on SCRC Subscribe to Microcapdaily.com Right Now by entering your Email in the box below
Jun Liang, Manager of Forbes Ltd. in Shenzhen, China, is arranging for ScripsAmerica to meet with its pharmacy and hospital buying networks as part of an upcoming sales agreement that would introduce RapiMed(R) into the Chinese OTC drug market. Liang said, “ScripsAmerica’s RapiMed Products are uniquely formulated to meet China’s market needs. It allows the country’s pharmaceutical companies, hospitals, nursing facilities, research institutes and the military to adapt RapiMed to fit their situations.”
On October 6 SCRC announced that the Company’s managed specialty pharmacy reported $5,457,137 in approved orders during the month of September 2014. The pharmacy’s September revenue represented a 12% increase over the previous month and increased its annual run rate to over $65 million.
We have a Monster Pick Coming. Subscribe Right Now!
“Since Scrips began managing Main Avenue Pharmacy six months ago, its sales revenue generated by filling the Company’s prescriptions has steadily increased each month, reaching nearly $5.5 million in September. We expect the revenue from ScripsAmerica’s specialty pharmacy operations to remain strong during the fourth quarter and potentially increase in 2015 as we continue to expand our presence in this market across the country,” commented ScripsAmerica’s CEO Bob Schneiderman.
SCRC is making a highly explosive move up on heavy volume after the stock hit a recent all-time low of $0.0815. The Company has been announcing significant growth in revenues that puts SCRC above most that trade on this exchange. Currently trading at a $16 million market valuation investors are accumulation betting the $0.0815 was the all-time low and reversal point that SCRC will move up off of.
Sign Up now for our 100% FREE Penny Stock Newsletter
Disclosure: we hold no position in SCRC either long or short and we have not been compensated for this article.